326 results on '"Swanson, Gregory P."'
Search Results
2. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
3. Aircrew deployments: A flight surgeon's story
4. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
5. The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis
6. The effect of radiation therapy on post-prostatectomy urinary function
7. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
8. p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study
9. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
10. Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation
11. Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort
12. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008
13. Prostate Cancer in Patients With High Prostate-Specific Antigen Levels but Otherwise Very-Low-Risk Disease Behaves Like Prostate Cancer in High-Risk Patients
14. Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols
15. Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease
16. Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy
17. Prostate-specific Antigen Mass Density—A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution
18. Lymphocyte response and recovery to radiation therapy alone
19. Image-Guided Radiation Therapy for Renal Cell Carcinoma
20. Unresectable bulky Thymic Cancer rendered operable with Radiation Therapy
21. A Better Understanding of Lymphatic Drainage of the Prostate With Modern Imaging and Surgical Techniques
22. Tumor cytoreduction results in better response to androgen ablation—a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer
23. Reference Results for Blood Parameter Changes and Recovery after Pelvic Radiation without Chemotherapy
24. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
25. Validation of Postoperative Nomograms in Prostate Cancer Patients with Long-term Follow-up
26. Pathological Characteristics of Low Risk Prostate Cancer Based on Totally Embedded Prostatectomy Specimens
27. The Prognostic Impact of Seminal Vesicle Involvement Found at Prostatectomy and the Effects of Adjuvant Radiation: Data From Southwest Oncology Group 8794
28. Tolerance of Phellodendron amurense Bark Extract (Nexrutine®) in Patients with Human Prostate Cancer
29. The effect of pelvic radiation alone on lymphocyte subgroups
30. Ad Astra – telomeres in space!
31. Bone Density Changes Following Radiotherapy to Vertebral Metastases
32. Primary hormone therapy for locally advanced prostate cancer
33. Adjuvant radiotherapy for high-risk patients following radical prostatectomy
34. Pathologic findings at radical prostatectomy: Risk factors for failure and death
35. Urologists’ Attitudes Regarding Cancer Clinical Research
36. Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?
37. Multidisciplinary management of prostate malignancy
38. Telomere Length Dynamics and Chromosomal Instability for Predicting Individual Radiosensitivity and Risk via Machine Learning
39. Molecular Markers of Prostate Cancer Outcome
40. Management of Locally Advanced Prostate Cancer: Past, Present, Future
41. Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024
42. Cell‐cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone
43. Short-Term Haematogical Effects of Androgen Deprivation and Radiotherapy in Prostate Cancer Patients
44. Gleason Score Evolution and the Effect on Prostate Cancer Outcomes
45. Ability of cell-cycle progression score to predict risk for progression to metastatic disease and disease-specific mortality in prostate cancer patients after prostatectomy.
46. Telomere length and chromosomal instability for predicting individual radiosensitivity and risk via machine learning
47. Long-Term Follow-Up after Prostatectomy for Prostate Cancer and the Need for Active Monitoring
48. Ad Astra – telomeres in space!
49. Current Status of Lymph Node-Positive Prostate Cancer: Incidence and predictors of outcome
50. Treatment options in lymph node-positive prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.